Jul 13, 2022
Dr. Judy Chou is the President and CEO of AltruBio which is developing novel immunomodulators to treat immunological diseases such as autoimmune and inflammatory diseases. Their first-in-class agnostic antibody has a unique mechanism to regulate T cell homeostasis. Currently, there is a clinical trial for SR-aGVHD, steroid-refractory acute graft-host disease and an investigation is underway into using their second-generation molecule to treat ulcerative colitis.
Judy explains, "So we have this specific approach, only targeting those activated or the so-called over-activated T cell. So when the T cell is supposed to come down to quieten and to bring back to homeostasis, go back to balance, it did not. It keeps going and going and going. And we have identified the key target to turn it down to the balance point to tell those T cells it's time to rest, to downregulate this group of T cells. And that's the approach you are taking. That's why AltruBio is so unique in addressing immunological diseases."
#AltruBio #ImmuneModulators #ImmuneDiseases #TCells #GVHD